[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Status:
Completed
Trial end date:
2017-04-30
Target enrollment:
Participant gender:
Summary
[F-18] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan
to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone
marrow will help maintain blood counts. This would impact chemotherapy administration.
Phase:
Phase 2
Details
Lead Sponsor:
John M. Buatti
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)